Searchable abstracts of presentations at key conferences in endocrinology

ea0081p481 | Thyroid | ECE2022

Unexpected alterations in thyroid status: a case of alemtuzumab-induced Graves’ disease with fluctuating course

Filipa Araujo Barbara , Lavrador Mariana , Araujo Catia , Ribeiro Ana , Paiva Sandra , Paiva Isabel

Introduction: Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved for the treatment of relapsingāˆ’remitting multiple sclerosis (RRMS). Through an immune reconstitution mechanism, it leads to thyroid autoimmunity in 35% of cases, with GravesĀ’ disease (GD) being the most common presentation. Alemtuzumab-induced GD exhibits distinctive clinical and immunological features, with rarely reported cases of fluctuating thyroid status with documented both blockin...

ea0090p296 | Adrenal and Cardiovascular Endocrinology | ECE2023

Cardiometabolic and Kidney Biomarker Effects of Gender-affirming Hormone Therapy in Transgender Males

Filipa Araujo Barbara , Lopes Sofia , Ferreira Mafalda , Ruas Luisa , Paiva Sandra , Paiva Isabel

Introduction: Testosterone-based gender-affirming hormone therapy (GAHT) may have negative consequences on cardiovascular risk, with reported increased blood pressure, decreased HDL-cholesterol, and weight gain. Still, data on cardiometabolic changes in transgender men on GAHT remain controversial. Testosterone-based GAHT also modifies body composition and lean muscle mass, but the degree to which affects serum creatinine and other measures of kidney function is still not clea...

ea0090p308 | Calcium and Bone | ECE2023

Therapeutic Options for Inoperable Local Relapse of Parathyroid Carcinoma with Symptomatic Hypercalcemia: a Case Report

Filipa Araujo Barbara , Carreira Ana , Moreno Carolina , Rodrigues Dircea , Paiva Sandra , Paiva Isabel

Introduction: Parathyroid carcinoma (PC) is an extremely rare malignancy. A complete surgical excision is often difficult, and persistent/recurrent disease occurs in up to 65% of cases. Progression often leads to symptomatic hypercalcemia, the major contributor to poor quality of life and mortality. Treatment options beyond surgical resection are limited. Denosumab is an approved therapy for refractory hypercalcemia of malignancy, and its use in unresectable PC has been descri...

ea0081p399 | Pituitary and Neuroendocrinology | ECE2022

Familial neurohypophyseal diabetes insipidus: an extremely rare report of a family with a nonsense mutation in the arginine vasopressin gene

Ramalho Diogo , Serra-Caetano Joana , Cardoso Rita , Rosinha Patricia , Filipa Araujo Barbara , Rua Ines , Rodrigues Orlando , Dinis Isabel , Mirante Alice

Introduction: Familial neurohypophyseal diabetes insipidus (FNDI) is a rare form of central diabetes insipidus (CDI) characterized by childhood-onset progressive polydipsia and polyuria due to mutations in the arginine vasopressin-neurophysin II (AVP-NPII) gene.Case description: Two male siblings were referred at 1 month of age to exclude CDI owing to a family history of CDI in the father and paternal grandfather. The proband was the fa...

ea0099ep796 | Calcium and Bone | ECE2024

Severe Hypercalcemia After Parathyroidectomy: When the Unexpected Happens

Carvalho Tania , Rodrigues Gustavo , Filipa Araujo Barbara , Saraiva Joana , Ventura Mara , Gouveia Sofia , Rodrigues Dircea , Paiva Isabel

Introduction: Severe hypercalcemia is defined as a total serum calcium level >14 mg/dl or ionized calcium >10 mg/dl . The most common causes are primary hyperparathyroidism (PHPT) and neoplasms (90% of cases). Vitamin D intoxication is an extremely rare cause. Case Report: A 56-year-old man presented to the emergency department with vomiting, generalized weakness and complaints of imbalance over one week. Upon physical examination, he displayed c...